Newsletter Subject

Revenge of the (finance) nerds 🤓

From

360wallstreet.io

Email Address

360wallstreet@mail.360wallstreet.io

Sent On

Mon, Oct 30, 2023 01:03 PM

Email Preheader Text

And other stocks spiking on news ?

And other stocks spiking on news                                                                                                                                                                                                                                                                                                                                                                                                                 Good day, 360 – Here are our top investing ideas today – these setups look primed! Be the best prepared trader on the Street. And be sure to opt in to the [special Market Navigator trial]( ending soon! CHRS - Up over 18% in pre-market after receiving FDA approval NRDS - 2nd day play after closing 40% higher on Friday on earnings beat BPTS - Up over 14% after announcing partnership with Innovation Solutions Pharma to accelerate market access for Sarconeos (BIO101) in Brazil I know I catch some heat when a pick doesn’t go the way I want. But c’mon… you gotta give “El Jefe” some credit this month! Last week, [Bullseye traders]( hit gold once again with MARA calls which had an INSANE potential move of over 400% higher from my entry price. Note: Trading is hard, results not guaranteed and should not be expected to be replicated typically The week before that, we absolutely crushed NVDA puts as that stock was destroyed. The options I called? They had the chance to move over 300% higher! Looking back another week, we all had the chance to buy ERX calls → as I said, energy stocks were going to be one of the few sectors that would do well at the start of the new war brewing. Those made a nearly 200% move higher. It has been a really fun month, and I have been enjoying putting some profits on the board. And although not all my trade ideas work out this perfectly, I encourage you to check out [my trading hub]( to see WHY I’ve traded WHAT I’ve traded… [And make sure you're on the list for my next Bullseye Pick of the Week](🎯 CHRS - Up over 18% in pre-market after receiving FDA approval Coherus BioSciences (CHRS) is a biopharmaceutical company that focuses on the biosimilar and immuno-oncology market primarily in the United States. Late Friday, [the company announced]( that it had received FDA approval for LOQTORZI(™) in all lines of treatment for recurrent and metastatic Nasopharyngeal Carcinoma (NPC). LOQTORZI is expected to be available in the United States in Q1 2024. The stock is up over 18% in pre-market after the news. The $3.05 area was resistance in the after-hours and acted as support in the pre-market. Above it, targets to the upside are $3.19, $3.30, $3.50 and then the pre-market high at $3.62. Beyond that, $4, $4.50 and $5 come into play. Below $3.06, there is potential support at $2.90 and then a gap to fill at $2.64. NRDS - 2nd day play after closing 40% higher on Friday on earnings beat NerdWallet (NRDS) operates a digital platform that provides consumer-driven advice about personal finance by connecting individuals and small and mid-sized businesses with financial products providers in the United States and internationally. In after-hours Thursday [NRDS reported]( Q3 EPS of -$0.01 vs the -$0.08 estimate. Revenue came in at $152.8 million vs the consensus estimate of $144.26 million. After the positive earnings, NRDS closed Friday up over 40% and is one to have on your radar today. The $9.60 area was resistance on Friday. Above it, the first target for bulls is Friday’s high of $9.82. Beyond that, $10, $10.50, $11, $11.50 and $12.50 come into play. Below $9.60, there is potential support at $9.20, $9, $8, $7.50 and then a gap to fill at $6.64. BPTS - Up over 14% after announcing partnership with Innovation Solutions Pharma to accelerate market access for Sarconeos (BIO101) in Brazil Biophytis S.A. (BPTS) is a clinical-stage biotechnology company that focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Early this morning [the company announced]( a partnership with Innovation Solutions Pharma to accelerate market access for Sarconeos (BIO101) in Brazil. As part of this partnership, Innovative Solutions Pharma will represent Biophytis in front of the Brazilian agency ANVISA to lift the suspension of the Early Access Program (EAP) authorized at the beginning of 2022.This program will enable a maximum of 80 patients suffering from critical forms of COVID-19 to be treated for 28 days under mechanical ventilation in the intensive care units of Brazilian hospitals. The aim is to offer a therapeutic alternative to prevent death of these patients. There are still very few options available for treating severe forms of the disease. $0.79 area has acted as support so far in the pre-market Above it, the first major target for bulls is the pre-market high at $0.88. Beyond that, $1, $1.20 and $1.40 come into play. Below $0.79, there is potential support at $0.77 and then a gap to fill at $0.71. [Economic Calendar]( DISCLAIMER: To more fully understand any Ragingbull. com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [(. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. AnyRagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor(IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services. However, Ragingbull. com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. [tw]( Update your email preferences or unsubscribe [here]( © 2023 360wallstreet 62 Calef Hwy. #233 Lee, NH 03861, United States of America

Marketing emails from 360wallstreet.io

View More
Sent On

06/12/2024

Sent On

29/11/2024

Sent On

26/11/2024

Sent On

04/11/2024

Sent On

31/10/2024

Sent On

29/10/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.